Form 3 Filing for Chemomab Therapeutics Ltd.

This filing details the ownership of securities by John Lawler, Chief Development Officer of Chemomab Therapeutics Ltd. (CMMB). The filing, submitted on April 10, 2026, covers the period ending March 18, 2026. It includes information on both derivative and non-derivative holdings. Lawler directly owns various stock options, including those granted on January 24, 2022, July 11, 2023, and February 8, 2024, with specific vesting and exercisability dates. Additionally, the filing reports direct ownership of American Depositary Shares (ADS), including those subject to Restricted Stock Units (RSUs) granted on October 1, 2024, and April 10, 2025, with future vesting schedules. The filing was made under temporary relief for foreign private issuers.